Heat Shock Protein 47 in Thrombosis

Launched by UNIVERSITY OF AARHUS · Dec 9, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new blood marker called Heat Shock Protein 47 (HSP47) to see if it can help doctors understand and predict vascular diseases, which are conditions affecting blood vessels. The trial focuses on patients who have had serious health issues like deep vein thrombosis (a blood clot in a vein), heart attacks, or strokes. Researchers want to find out if levels of HSP47 in platelets (a type of blood cell involved in clotting) are higher in these patients compared to healthy individuals and whether these levels change over time. Additionally, they are exploring how HSP47 levels relate to how well platelets function and how quickly the body can break down clots.

To participate in the trial, you must be at least 18 years old and provide informed consent. Eligible participants include those diagnosed with acute venous thromboembolism, heart attacks, or strokes, as well as healthy volunteers who have no history of these conditions. Participants will give blood samples at the time of diagnosis and again after 3 and 12 months for follow-up. Healthy volunteers will only need to provide one blood sample. It’s important to note that the study is not yet recruiting participants, and it excludes individuals with certain medical conditions like severe kidney issues or blood disorders.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years of age or older
• • Informed consent
• VTE group:
• • Deep vein thrombosis confirmed on ultrasonography OR
• • Pulmonary embolism confirmed on computed tomography angiography (CTA)
• AMI group:
• • ST-segment elevation on electrocardiogram (ECG) AND
• • Culprit lesion(s) on coronary angiography
• Stroke group:
• • Stroke confirmed on magnetic resonance imaging AND
• • Atrial fibrillation (Detected on ECG, telemtry or Holter monitoring) AND
• • Stroke localisation classic for AFib: cortical, cerebellar, brainstem or subcortical \>1.5 cm in diameter
• Healthy group:
• • - Healthy
• Exclusion Criteria:
• • \<18 years of age
• • no informed consent
• • Known haematological disorders
• • Active haematological malignancy
• • Severe renal insufficiency defined as eGFR \<15 or dialysis
• • VTE - Pulmonary embolism incidentally detected by CTA conducted for purposes unrelated to pulmonary embolism assessment without concomitant DVT
• • AMI
• • Coronary dissection
• • Takotsubo cardiomyopathy
• • Stroke
• • - Stroke from other causes, e.g. findings pointing towards large vessel disease
• • Healthy
• • Known acute or chronic disease
• • Prior VTE, AMI, stroke or other thromboembolic event